Clinical Trial Update: XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for XLCART001 in relapsed/refractory/high-risk B-cell malignancies is underway, with status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• XLCART001

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Lymphoma, B-Cell, Leukemia, B-cell | Phase 2 | Status: UNKNOWN